Exact Mass: 751.5784286
Exact Mass Matches: 751.5784286
Found 481 metabolites which its exact mass value is equals to given mass value 751.5784286,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
PE(P-18:0/20:4(5Z,8Z,11Z,14Z))
PE(P-18:0/20:4(5Z,8Z,11Z,14Z)) belongs to a class of glycerophospholipids in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the sn-1 and sn-2 positions. Fatty acids containing 16, 18, and 20 carbons are the most common (LipidMAPS). PE(P-18:0/20:4(5Z,8Z,11Z,14Z)) is a phosphatidylethanolamine (PE or GPEtn) and consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of arachidonic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver, and kidney, while the arachidonic acid moiety is derived from animal fats and eggs. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signalling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodelling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4, and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine, and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0, and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. A class of glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphocholines can have many different combinations of fatty acids of varying lengths and saturation attached at the SN-1 and SN-2 positions. fatty acids containing 16, 18 and 20 carbons are the most common. (LipidMAPS)
PE(20:3(5Z,8Z,11Z)/P-18:1(11Z))
C43H78NO7P (751.5515607999998)
PE(20:3(5Z,8Z,11Z)/P-18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:3(5Z,8Z,11Z)/P-18:1(11Z)), in particular, consists of one chain of mead acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The mead acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PE(20:3(5Z,8Z,11Z)/P-18:1(9Z))
C43H78NO7P (751.5515607999998)
PE(20:3(5Z,8Z,11Z)/P-18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:3(5Z,8Z,11Z)/P-18:1(9Z)), in particular, consists of one chain of mead acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The mead acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(20:3(5Z,8Z,11Z)/P-18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:3(5Z,8Z,11Z)/P-18:1(9Z)), in particular, consists of one chain of mead acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The mead acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(20:3(8Z,11Z,14Z)/P-18:1(11Z))
C43H78NO7P (751.5515607999998)
PE(20:3(8Z,11Z,14Z)/P-18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:3(8Z,11Z,14Z)/P-18:1(11Z)), in particular, consists of one chain of homo-g-linolenic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The homo-g-linolenic acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(20:3(8Z,11Z,14Z)/P-18:1(11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:3(8Z,11Z,14Z)/P-18:1(11Z)), in particular, consists of one chain of homo-g-linolenic acid at the C-1 position and one chain of plasmalogen 18:1n7 at the C-2 position. The homo-g-linolenic acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(20:3(8Z,11Z,14Z)/P-18:1(9Z))
C43H78NO7P (751.5515607999998)
PE(20:3(8Z,11Z,14Z)/P-18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:3(8Z,11Z,14Z)/P-18:1(9Z)), in particular, consists of one chain of homo-g-linolenic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The homo-g-linolenic acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(20:3(8Z,11Z,14Z)/P-18:1(9Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:3(8Z,11Z,14Z)/P-18:1(9Z)), in particular, consists of one chain of homo-g-linolenic acid at the C-1 position and one chain of plasmalogen 18:1n9 at the C-2 position. The homo-g-linolenic acid moiety is derived from fish oils, liver and kidney, while the plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(20:4(5Z,8Z,11Z,14Z)/P-18:0)
C43H78NO7P (751.5515607999998)
PE(20:4(5Z,8Z,11Z,14Z)/P-18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:4(5Z,8Z,11Z,14Z)/P-18:0), in particular, consists of one chain of arachidonic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The arachidonic acid moiety is derived from animal fats and eggs, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(20:4(5Z,8Z,11Z,14Z)/P-18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:4(5Z,8Z,11Z,14Z)/P-18:0), in particular, consists of one chain of arachidonic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The arachidonic acid moiety is derived from animal fats and eggs, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(20:4(8Z,11Z,14Z,17Z)/P-18:0)
C43H78NO7P (751.5515607999998)
PE(20:4(8Z,11Z,14Z,17Z)/P-18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:4(8Z,11Z,14Z,17Z)/P-18:0), in particular, consists of one chain of eicsoatetraenoic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The eicsoatetraenoic acid moiety is derived from fish oils, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(20:4(8Z,11Z,14Z,17Z)/P-18:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(20:4(8Z,11Z,14Z,17Z)/P-18:0), in particular, consists of one chain of eicsoatetraenoic acid at the C-1 position and one chain of plasmalogen 18:0 at the C-2 position. The eicsoatetraenoic acid moiety is derived from fish oils, while the plasmalogen 18:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(22:4(7Z,10Z,13Z,16Z)/P-16:0)
C43H78NO7P (751.5515607999998)
PE(22:4(7Z,10Z,13Z,16Z)/P-16:0) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(22:4(7Z,10Z,13Z,16Z)/P-16:0), in particular, consists of one chain of adrenic acid at the C-1 position and one chain of plasmalogen 16:0 at the C-2 position. The adrenic acid moiety is derived from animal fats, while the plasmalogen 16:0 moiety is derived from animal fats, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PE(P-16:0/22:4(7Z,10Z,13Z,16Z))
C43H78NO7P (751.5515607999998)
PE(P-16:0/22:4(7Z,10Z,13Z,16Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-16:0/22:4(7Z,10Z,13Z,16Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of adrenic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the adrenic acid moiety is derived from animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-16:0/22:4(7Z,10Z,13Z,16Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-16:0/22:4(7Z,10Z,13Z,16Z)), in particular, consists of one chain of plasmalogen 16:0 at the C-1 position and one chain of adrenic acid at the C-2 position. The plasmalogen 16:0 moiety is derived from animal fats, liver and kidney, while the adrenic acid moiety is derived from animal fats. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(P-18:0/20:4(8Z,11Z,14Z,17Z))
C43H78NO7P (751.5515607999998)
PE(P-18:0/20:4(8Z,11Z,14Z,17Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:0/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of eicsoatetraenoic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the eicsoatetraenoic acid moiety is derived from fish oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:0/20:4(8Z,11Z,14Z,17Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:0/20:4(8Z,11Z,14Z,17Z)), in particular, consists of one chain of plasmalogen 18:0 at the C-1 position and one chain of eicsoatetraenoic acid at the C-2 position. The plasmalogen 18:0 moiety is derived from animal fats, liver and kidney, while the eicsoatetraenoic acid moiety is derived from fish oils. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(P-18:1(11Z)/20:3(5Z,8Z,11Z))
C43H78NO7P (751.5515607999998)
PE(P-18:1(11Z)/20:3(5Z,8Z,11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(11Z)/20:3(5Z,8Z,11Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of mead acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the mead acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids.
PE(P-18:1(11Z)/20:3(8Z,11Z,14Z))
C43H78NO7P (751.5515607999998)
PE(P-18:1(11Z)/20:3(8Z,11Z,14Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(11Z)/20:3(8Z,11Z,14Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of homo-g-linolenic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the homo-g-linolenic acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:1(11Z)/20:3(8Z,11Z,14Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(11Z)/20:3(8Z,11Z,14Z)), in particular, consists of one chain of plasmalogen 18:1n7 at the C-1 position and one chain of homo-g-linolenic acid at the C-2 position. The plasmalogen 18:1n7 moiety is derived from animal fats, liver and kidney, while the homo-g-linolenic acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
PE(P-18:1(9Z)/20:3(5Z,8Z,11Z))
C43H78NO7P (751.5515607999998)
PE(P-18:1(9Z)/20:3(5Z,8Z,11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(9Z)/20:3(5Z,8Z,11Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of mead acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the mead acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. While most phospholipids have a saturated fatty acid on C-1 and an unsaturated fatty acid on C-2 of the glycerol backbone, the fatty acid distribution at the C-1 and C-2 positions of glycerol within phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. PEs are neutral zwitterions at physiological pH. They mostly have palmitic or stearic acid on carbon 1 and a long chain unsaturated fatty acid (e.g. 18:2, 20:4 and 22:6) on carbon 2. PE synthesis can occur via two pathways. The first requires that ethanolamine be activated by phosphorylation and then coupled to CDP. The ethanolamine is then transferred from CDP-ethanolamine to phosphatidic acid to yield PE. The second involves the decarboxylation of PS. Plasmalogens are glycerol ether phospholipids. They are of two types, alkyl ether (-O-CH2-) and alkenyl ether (-O-CH=CH-). Dihydroxyacetone phosphate (DHAP) serves as the glycerol precursor for the synthesis of plasmalogens. Three major classes of plasmalogens have been identified: choline, ethanolamine and serine derivatives. Ethanolamine plasmalogen is prevalent in myelin. Choline plasmalogen is abundant in cardiac tissue. Usually, the highest proportion of the plasmalogen form is in the ethanolamine class with rather less in choline, and commonly little or none in other phospholipids such as phosphatidylinositol. In choline plasmalogens of most tissues, a higher proportion is often of the O-alkyl rather than the O-alkenyl form, but the reverse tends to be true in heart lipids. In animal tissues, the alkyl and alkenyl moieties in both non-polar and phospholipids tend to be rather simple in composition with 16:0, 18:0 and 18:1 (double bond in position 9) predominating. Ether analogues of triacylglycerols, i.e. 1-alkyldiacyl-sn-glycerols, are present at trace levels only if at all in most animal tissues, but they can be major components of some marine lipids. PE(P-18:1(9Z)/20:3(5Z,8Z,11Z)) is a phosphatidylethanolamine (PE or GPEtn). It is a glycerophospholipid in which a phosphorylethanolamine moiety occupies a glycerol substitution site. As is the case with diacylglycerols, glycerophosphoethanolamines can have many different combinations of fatty acids of varying lengths and saturation attached at the C-1 and C-2 positions. Fatty acids containing 16, 18 and 20 carbons are the most common. PE(P-18:1(9Z)/20:3(5Z,8Z,11Z)), in particular, consists of one chain of plasmalogen 18:1n9 at the C-1 position and one chain of mead acid at the C-2 position. The plasmalogen 18:1n9 moiety is derived from animal fats, liver and kidney, while the mead acid moiety is derived from fish oils, liver and kidney. Phospholipids, are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling.
Phosphatidylethanolamine alkenyl 16:0-22:4
C43H78NO7P (751.5515607999998)
Phosphatidylethanolamine alkenyl 18:0-20:4
C43H78NO7P (751.5515607999998)
1-O-(alpha-D-glucopyranosyl)-(2S,3R,4E,8E,10E)-2-[(2R,3E)-2-hydroxyoctadec-3-enoylamino]-9-methyloctadeca-4,8,10-triene-1,3-diol|sarcoehrenoside A
(2-aminoethoxy)[2-[icosa-5.8.11.14-tetraenoyloxy]-3-[octadec-1-en-1-yloxy]propoxy]phosphinic acid
C43H78NO7P (751.5515607999998)
PE(O-16:0/22:5)
C43H78NO7P (751.5515607999998)
PE(O-18:0/20:5)
C43H78NO7P (751.5515607999998)
PE(38:4)
C43H78NO7P (751.5515607999998)
1-Eicsoate
C43H78NO7P (751.5515607999998)
1-alkyl-2-acyl-glycerophosphoethanolamine
C43H78NO7P (751.5515607999998)
PE(P-18:0/20:4)
C43H78NO7P (751.5515607999998)
PE(P-20:0/18:4(6Z,9Z,12Z,15Z))
C43H78NO7P (751.5515607999998)
PE O-38:5
C43H78NO7P (751.5515607999998)
[(2R)-2,3-di(hexadecanoyloxy)propyl] 2-(trimethylazaniumyl)ethyl phosphate,hydrate
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(6E,8Z,11Z,14Z)-5-oxoicosa-6,8,11,14-tetraenoyl]amino]heptadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C42H76N2O7P+ (751.5389855999999)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(5Z,8Z,11Z,13E)-15-oxoicosa-5,8,11,13-tetraenoyl]amino]heptadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C42H76N2O7P+ (751.5389855999999)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,16E,18R)-18-hydroxyicosa-5,8,11,14,16-pentaenoyl]amino]heptadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C42H76N2O7P+ (751.5389855999999)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(5Z,8Z,11Z,13E,17Z)-16-hydroxyicosa-5,8,11,13,17-pentaenoyl]amino]heptadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C42H76N2O7P+ (751.5389855999999)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(5Z,8Z,10E,14Z,17Z)-12-hydroxyicosa-5,8,10,14,17-pentaenoyl]amino]heptadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C42H76N2O7P+ (751.5389855999999)
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(6E,8Z,11Z,14Z,17Z)-5-hydroxyicosa-6,8,11,14,17-pentaenoyl]amino]heptadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C42H76N2O7P+ (751.5389855999999)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(5Z,8Z,11Z)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C42H76N2O7P+ (751.5389855999999)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(5Z,8Z)-10-[3-[(Z)-oct-2-enyl]oxiran-2-yl]deca-5,8-dienoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C42H76N2O7P+ (751.5389855999999)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(Z)-7-[3-[(2Z,5Z)-undeca-2,5-dienyl]oxiran-2-yl]hept-5-enoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C42H76N2O7P+ (751.5389855999999)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[4-[3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trienyl]oxiran-2-yl]butanoylamino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C42H76N2O7P+ (751.5389855999999)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C42H76N2O7P+ (751.5389855999999)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(5R,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C42H76N2O7P+ (751.5389855999999)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,19S)-19-hydroxyicosa-5,8,11,14-tetraenoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C42H76N2O7P+ (751.5389855999999)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,18R)-18-hydroxyicosa-5,8,11,14-tetraenoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C42H76N2O7P+ (751.5389855999999)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z)-17-hydroxyicosa-5,8,11,14-tetraenoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C42H76N2O7P+ (751.5389855999999)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(5Z,8Z,11Z,14Z,16R)-16-hydroxyicosa-5,8,11,14-tetraenoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C42H76N2O7P+ (751.5389855999999)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(5Z,8Z,11Z,13E,15S)-15-hydroxyicosa-5,8,11,13-tetraenoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C42H76N2O7P+ (751.5389855999999)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C42H76N2O7P+ (751.5389855999999)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(5E,8Z,11R,12Z,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C42H76N2O7P+ (751.5389855999999)
2-[hydroxy-[(2S,3R,4E,8Z)-3-hydroxy-2-[[(5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoyl]amino]heptadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C42H76N2O7P+ (751.5389855999999)
N-arachidonoyl-1-(1Z-octadecenyl)-sn-glycero-3-phosphoethanolamine
C43H78NO7P (751.5515607999998)
2-[[(2S,3S,4R)-3,4-dihydroxy-2-(2-hydroxyoctadecanoylamino)-15-methylhexadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C40H84N2O8P+ (751.5964974000001)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-octadeca-9,12-dienoxy]propan-2-yl] (11Z,14Z,17Z)-icosa-11,14,17-trienoate
C43H78NO7P (751.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-hexadec-9-enoxy]propan-2-yl] (10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoate
C43H78NO7P (751.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-octadec-9-enoxy]propan-2-yl] (8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoate
C43H78NO7P (751.5515607999998)
[3-[2-aminoethoxy(hydroxy)phosphoryl]oxy-2-hydroxypropyl] (23Z,26Z,29Z,32Z,35Z)-octatriaconta-23,26,29,32,35-pentaenoate
C43H78NO7P (751.5515607999998)
[2-[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoyl]oxy-3-nonoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
(6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z,36Z,39Z)-N-[(E)-1,3-dihydroxynon-4-en-2-yl]dotetraconta-6,9,12,15,18,21,24,27,30,33,36,39-dodecaenamide
2-[2-[(15Z,18Z)-hexacosa-15,18-dienoyl]oxy-3-octanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(11Z,14Z)-henicosa-11,14-dienoyl]oxy-3-tridecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(9Z,12Z)-hexadeca-9,12-dienoyl]oxy-3-octadecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-hexadecanoyloxy-2-[(9Z,12Z)-octadeca-9,12-dienoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-heptadecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(Z)-nonadec-9-enoyl]oxy-3-[(Z)-pentadec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2,3-bis[[(Z)-heptadec-9-enoyl]oxy]propoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-decanoyloxy-2-[(13Z,16Z)-tetracosa-13,16-dienoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxy-3-pentadecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(Z)-henicos-11-enoyl]oxy-3-[(Z)-tridec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[3-[(Z)-hexadec-9-enoyl]oxy-2-[(Z)-octadec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(13Z,16Z)-docosa-13,16-dienoyl]oxy-3-dodecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(11Z,14Z)-icosa-11,14-dienoyl]oxy-3-tetradecanoyloxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
2-[2-[(Z)-icos-11-enoyl]oxy-3-[(Z)-tetradec-9-enoyl]oxypropoxy]-2-[2-(trimethylazaniumyl)ethoxy]acetate
(6Z,9Z,12Z,15Z,18Z,21Z,24Z,27Z,30Z,33Z)-N-[(4E,8E,12E)-1,3-dihydroxypentadeca-4,8,12-trien-2-yl]hexatriaconta-6,9,12,15,18,21,24,27,30,33-decaenamide
(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxydocos-11-enoyl]amino]docosa-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxyhenicos-9-enoyl]amino]tricosa-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxyoctadec-11-enoyl]amino]hexacosa-4,8,12-triene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(18Z,21Z)-2-hydroxytetracosa-18,21-dienoyl]amino]icosa-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(10Z,12Z)-2-hydroxyoctadeca-10,12-dienoyl]amino]hexacosa-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(14Z,16Z)-2-hydroxydocosa-14,16-dienoyl]amino]docosa-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(11Z,14Z)-2-hydroxyicosa-11,14-dienoyl]amino]tetracosa-4,8-diene-1-sulfonic acid
(4E,8E)-3-hydroxy-2-[[(11Z,14Z)-2-hydroxyhexacosa-11,14-dienoyl]amino]octadeca-4,8-diene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxytricos-11-enoyl]amino]henicosa-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxynonadec-9-enoyl]amino]pentacosa-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxyhexacos-11-enoyl]amino]octadeca-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxypentacos-11-enoyl]amino]nonadeca-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxytetracos-11-enoyl]amino]icosa-4,8,12-triene-1-sulfonic acid
(4E,8E,12E)-3-hydroxy-2-[[(Z)-2-hydroxyicos-11-enoyl]amino]tetracosa-4,8,12-triene-1-sulfonic acid
[3-[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoxy]-2-nonanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
[2-heptanoyloxy-3-[(13Z,16Z,19Z,22Z,25Z)-octacosa-13,16,19,22,25-pentaenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
(E)-2-[[(11Z,14Z)-henicosa-11,14-dienoyl]amino]-3-hydroxytetracos-4-ene-1-sulfonic acid
C45H85NO5S (751.6148119999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-docos-13-enoxy]propan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
C43H78NO7P (751.5515607999998)
(4E,8E,12E)-3-hydroxy-2-(tetracosanoylamino)henicosa-4,8,12-triene-1-sulfonic acid
C45H85NO5S (751.6148119999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoxy]propan-2-yl] dodecanoate
C43H78NO7P (751.5515607999998)
(E)-3-hydroxy-2-[[(13Z,16Z)-tetracosa-13,16-dienoyl]amino]henicos-4-ene-1-sulfonic acid
C45H85NO5S (751.6148119999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-icos-11-enoxy]propan-2-yl] (6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoate
C43H78NO7P (751.5515607999998)
(4E,8E)-3-hydroxy-2-[[(Z)-tetracos-13-enoyl]amino]henicosa-4,8-diene-1-sulfonic acid
C45H85NO5S (751.6148119999999)
(4E,8E,12E)-2-(hexacosanoylamino)-3-hydroxynonadeca-4,8,12-triene-1-sulfonic acid
C45H85NO5S (751.6148119999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoxy]propan-2-yl] tetradecanoate
C43H78NO7P (751.5515607999998)
(4E,8E,12E)-3-hydroxy-2-(nonadecanoylamino)hexacosa-4,8,12-triene-1-sulfonic acid
C45H85NO5S (751.6148119999999)
3-hydroxy-2-[[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoyl]amino]henicosane-1-sulfonic acid
C45H85NO5S (751.6148119999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z)-icosa-11,14-dienoxy]propan-2-yl] (9Z,12Z,15Z)-octadeca-9,12,15-trienoate
C43H78NO7P (751.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(13Z,16Z,19Z,22Z,25Z)-octacosa-13,16,19,22,25-pentaenoxy]propan-2-yl] decanoate
C43H78NO7P (751.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-tetradecoxypropan-2-yl] (9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoate
C43H78NO7P (751.5515607999998)
(4E,8E)-3-hydroxy-2-[[(Z)-nonadec-9-enoyl]amino]hexacosa-4,8-diene-1-sulfonic acid
C45H85NO5S (751.6148119999999)
(E)-3-hydroxy-2-[[(9Z,12Z)-nonadeca-9,12-dienoyl]amino]hexacos-4-ene-1-sulfonic acid
C45H85NO5S (751.6148119999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-decoxypropan-2-yl] (13Z,16Z,19Z,22Z,25Z)-octacosa-13,16,19,22,25-pentaenoate
C43H78NO7P (751.5515607999998)
(4E,8E,12E)-3-hydroxy-2-(icosanoylamino)pentacosa-4,8,12-triene-1-sulfonic acid
C45H85NO5S (751.6148119999999)
2-[[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoyl]amino]-3-hydroxynonadecane-1-sulfonic acid
C45H85NO5S (751.6148119999999)
(4E,8E,12E)-2-(henicosanoylamino)-3-hydroxytetracosa-4,8,12-triene-1-sulfonic acid
C45H85NO5S (751.6148119999999)
(4E,8E,12E)-3-hydroxy-2-(tricosanoylamino)docosa-4,8,12-triene-1-sulfonic acid
C45H85NO5S (751.6148119999999)
2-[[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]amino]-3-hydroxytricosane-1-sulfonic acid
C45H85NO5S (751.6148119999999)
(E)-3-hydroxy-2-[[(11Z,14Z)-icosa-11,14-dienoyl]amino]pentacos-4-ene-1-sulfonic acid
C45H85NO5S (751.6148119999999)
(4E,8E)-3-hydroxy-2-[[(Z)-icos-11-enoyl]amino]pentacosa-4,8-diene-1-sulfonic acid
C45H85NO5S (751.6148119999999)
(4E,8E,12E)-2-(docosanoylamino)-3-hydroxytricosa-4,8,12-triene-1-sulfonic acid
C45H85NO5S (751.6148119999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoxy]propan-2-yl] (Z)-tetradec-9-enoate
C43H78NO7P (751.5515607999998)
(E)-2-[[(13Z,16Z)-docosa-13,16-dienoyl]amino]-3-hydroxytricos-4-ene-1-sulfonic acid
C45H85NO5S (751.6148119999999)
(E)-2-[[(15Z,18Z)-hexacosa-15,18-dienoyl]amino]-3-hydroxynonadec-4-ene-1-sulfonic acid
C45H85NO5S (751.6148119999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(13Z,16Z)-docosa-13,16-dienoxy]propan-2-yl] (7Z,10Z,13Z)-hexadeca-7,10,13-trienoate
C43H78NO7P (751.5515607999998)
(4E,8E)-2-[[(Z)-docos-13-enoyl]amino]-3-hydroxytricosa-4,8-diene-1-sulfonic acid
C45H85NO5S (751.6148119999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]propan-2-yl] (Z)-docos-13-enoate
C43H78NO7P (751.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-icosoxypropan-2-yl] (3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoate
C43H78NO7P (751.5515607999998)
(4E,8E)-2-[[(Z)-hexacos-15-enoyl]amino]-3-hydroxynonadeca-4,8-diene-1-sulfonic acid
C45H85NO5S (751.6148119999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]propan-2-yl] (13Z,16Z)-docosa-13,16-dienoate
C43H78NO7P (751.5515607999998)
(4E,8E,12E)-3-hydroxy-2-(pentacosanoylamino)icosa-4,8,12-triene-1-sulfonic acid
C45H85NO5S (751.6148119999999)
(4E,8E)-2-[[(Z)-henicos-11-enoyl]amino]-3-hydroxytetracosa-4,8-diene-1-sulfonic acid
C45H85NO5S (751.6148119999999)
3-hydroxy-2-[[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]amino]pentacosane-1-sulfonic acid
C45H85NO5S (751.6148119999999)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-dodecoxypropan-2-yl] (11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoate
C43H78NO7P (751.5515607999998)
[2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxy-3-pentadecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
[3-[(9Z,12Z)-heptadeca-9,12-dienoxy]-2-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
[3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoxy]-2-[(Z)-nonadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
[2-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-3-[(Z)-nonadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
[3-[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoxy]-2-undecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
[2-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]oxy-3-tridecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
[2-[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoyl]oxy-3-undecoxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
[2-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]oxy-3-[(Z)-tridec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
[3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoxy]-2-[(9Z,12Z)-nonadeca-9,12-dienoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
[2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxy-3-[(Z)-pentadec-9-enoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
[2-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-3-[(9Z,12Z)-nonadeca-9,12-dienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
[3-heptadecoxy-2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
[3-[(Z)-heptadec-9-enoxy]-2-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
2-[4-(3-heptadecanoyloxy-12-hydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)pentanoylamino]ethanesulfonic acid
C43H77NO7S (751.5420452000001)
2-[4-[3-[(13Z,16Z)-docosa-13,16-dienoyl]oxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl]pentanoylamino]acetic acid
4-[2,3-bis[[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]oxy]propoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]oxy-2-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]oxy-2-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]propan-2-yl] octadecanoate
C43H78NO7P (751.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-hexadecoxypropan-2-yl] (7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoate
C43H78NO7P (751.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-octadecoxypropan-2-yl] (5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoate
C43H78NO7P (751.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z)-hexadeca-9,12-dienoxy]propan-2-yl] (10Z,13Z,16Z)-docosa-10,13,16-trienoate
C43H78NO7P (751.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z)-docosa-10,13,16-trienoxy]propan-2-yl] (9Z,12Z)-hexadeca-9,12-dienoate
C43H78NO7P (751.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoxy]propan-2-yl] (Z)-hexadec-9-enoate
C43H78NO7P (751.5515607999998)
[3-[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoxy]-2-pentadecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
[2-[(Z)-heptadec-9-enoyl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
[3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]-2-[(Z)-pentadec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
[2-[(9Z,12Z)-heptadeca-9,12-dienoyl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(11Z,14Z,17Z)-icosa-11,14,17-trienoxy]propan-2-yl] (9Z,12Z)-octadeca-9,12-dienoate
C43H78NO7P (751.5515607999998)
[3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoxy]-2-tridecanoyloxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(9Z,12Z,15Z)-octadeca-9,12,15-trienoxy]propan-2-yl] (11Z,14Z)-icosa-11,14-dienoate
C43H78NO7P (751.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(Z)-tetradec-9-enoxy]propan-2-yl] (12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoate
C43H78NO7P (751.5515607999998)
[3-[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoxy]-2-[(Z)-tridec-9-enoyl]oxypropyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoxy]propan-2-yl] hexadecanoate
C43H78NO7P (751.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoxy]propan-2-yl] (Z)-icos-11-enoate
C43H78NO7P (751.5515607999998)
[2-heptadecanoyloxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
C43H78NO7P (751.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoxy]propan-2-yl] icosanoate
C43H78NO7P (751.5515607999998)
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoxy]propan-2-yl] (Z)-octadec-9-enoate
C43H78NO7P (751.5515607999998)
(18Z,21Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradec-4-en-2-yl]tetracosa-18,21-dienamide
(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradeca-4,8-dien-2-yl]tetracos-11-enamide
(14Z,16Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadec-4-en-2-yl]docosa-14,16-dienamide
(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentacosa-4,8-dien-2-yl]tridec-8-enamide
(4Z,7Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxydocos-4-en-2-yl]hexadeca-4,7-dienamide
(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxypentadeca-4,8-dien-2-yl]tricos-11-enamide
(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxydocosa-4,8-dien-2-yl]hexadec-7-enamide
(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadeca-4,8-dien-2-yl]docos-11-enamide
(10Z,12Z)-N-[(E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicos-4-en-2-yl]octadeca-10,12-dienamide
(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyheptadeca-4,8-dien-2-yl]henicos-9-enamide
(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosa-4,8-dien-2-yl]octadec-11-enamide
(Z)-N-[(4E,8E)-3-hydroxy-1-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexacosa-4,8-dien-2-yl]dodec-5-enamide
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-octadec-1-enoxy]propan-2-yl] (5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoate
C43H78NO7P (751.5515607999998)
4-[3-[(E)-dec-4-enoyl]oxy-2-[(5E,8E,11E,14E,17E,20E,23E)-hexacosa-5,8,11,14,17,20,23-heptaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(9E,11E,13E,15E,17E)-henicosa-9,11,13,15,17-pentaenoyl]oxy-3-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(6E,9E)-dodeca-6,9-dienoyl]oxy-2-[(6E,9E,12E,15E,18E,21E)-tetracosa-6,9,12,15,18,21-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(6E,9E)-dodeca-6,9-dienoyl]oxy-3-[(6E,9E,12E,15E,18E,21E)-tetracosa-6,9,12,15,18,21-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
(E)-N-[(2S,3R,4E,6E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadeca-4,6-dien-2-yl]docos-13-enamide
(E)-N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,8-dien-2-yl]icos-11-enamide
4-[2-[(7E,9E,11E,13E,15E,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoyl]oxy-3-[(E)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-icos-1-enoxy]propan-2-yl] (6E,9E,12E,15E)-octadeca-6,9,12,15-tetraenoate
C43H78NO7P (751.5515607999998)
(E)-N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxydocosa-4,8-dien-2-yl]hexadec-9-enamide
(9E,12E)-N-[(E,2S,3R)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicos-8-en-2-yl]octadeca-9,12-dienamide
4-[3-[(7E,9E,11E,13E,15E,17E,19E)-docosa-7,9,11,13,15,17,19-heptaenoyl]oxy-2-[(E)-tetradec-9-enoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
(E)-N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradeca-4,8-dien-2-yl]tetracos-15-enamide
4-[2-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-3-[(6E,9E,12E,15E,18E)-tetracosa-6,9,12,15,18-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-3-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(E)-dec-4-enoyl]oxy-3-[(5E,8E,11E,14E,17E,20E,23E)-hexacosa-5,8,11,14,17,20,23-heptaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-3-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
(E)-N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhenicosa-4,8-dien-2-yl]heptadec-9-enamide
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-octadec-1-enoxy]propan-2-yl] (7E,10E,13E,16E)-icosa-7,10,13,16-tetraenoate
C43H78NO7P (751.5515607999998)
4-[3-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-2-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-2-[(5E,8E,11E)-icosa-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxy-2-[(11E,13E,15E)-octadeca-11,13,15-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-hexadec-1-enoxy]propan-2-yl] (7E,10E,13E,16E)-docosa-7,10,13,16-tetraenoate
C43H78NO7P (751.5515607999998)
4-[2-[(7E,9E,11E,13E,15E)-octadeca-7,9,11,13,15-pentaenoyl]oxy-3-[(11E,13E,15E)-octadeca-11,13,15-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoyl]amino]tetradec-8-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
4-[2-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-3-[(7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
(E)-N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicosa-4,8-dien-2-yl]octadec-9-enamide
4-[3-[(4E,7E)-deca-4,7-dienoyl]oxy-2-[(8E,11E,14E,17E,20E,23E)-hexacosa-8,11,14,17,20,23-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
(E)-N-[(2S,3R,4E,6E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxytetradeca-4,6-dien-2-yl]tetracos-15-enamide
4-[2-[(9E,11E,13E)-hexadeca-9,11,13-trienoyl]oxy-3-[(5E,8E,11E,14E,17E)-icosa-5,8,11,14,17-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[hydroxy-[(E,2S,3R)-3-hydroxy-2-[[(5E,8E,11E,14E)-tetracosa-5,8,11,14-tetraenoyl]amino]tetradec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
4-[3-[(7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoyl]oxy-2-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(7E,9E,11E,13E)-hexadeca-7,9,11,13-tetraenoyl]oxy-2-[(5E,8E,11E,14E)-icosa-5,8,11,14-tetraenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(8E,11E,14E)-heptadeca-8,11,14-trienoyl]oxy-3-[(4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2,3-bis[[(9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoyl]oxy]propoxy]-2-(trimethylazaniumyl)butanoate
(E)-N-[(2S,3R,4E,14E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoctadeca-4,14-dien-2-yl]icos-11-enamide
4-[3-[(8E,11E,14E)-heptadeca-8,11,14-trienoyl]oxy-2-[(4E,7E,10E,13E,16E)-nonadeca-4,7,10,13,16-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(4E,7E,10E,13E,16E,19E)-docosa-4,7,10,13,16,19-hexaenoyl]oxy-2-[(7E,9E)-tetradeca-7,9-dienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
(E)-N-[(2S,3R,4E,8E)-3-hydroxy-1-[(2S,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyhexadeca-4,8-dien-2-yl]docos-13-enamide
4-[2-[(4E,7E)-deca-4,7-dienoyl]oxy-3-[(8E,11E,14E,17E,20E,23E)-hexacosa-8,11,14,17,20,23-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
(9E,12E)-N-[(E,2S,3R)-3-hydroxy-1-[(2R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyicos-4-en-2-yl]octadeca-9,12-dienamide
4-[3-[(3E,6E,9E)-dodeca-3,6,9-trienoyl]oxy-2-[(6E,9E,12E,15E,18E)-tetracosa-6,9,12,15,18-pentaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(5E,7E,9E,11E,13E)-hexadeca-5,7,9,11,13-pentaenoyl]oxy-3-[(5E,8E,11E)-icosa-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[3-[(4E,7E)-hexadeca-4,7-dienoyl]oxy-2-[(7E,9E,11E,13E,15E,17E)-icosa-7,9,11,13,15,17-hexaenoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
[(2R)-1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-[(E)-icos-1-enoxy]propan-2-yl] (9E,11E,13E,15E)-octadeca-9,11,13,15-tetraenoate
C43H78NO7P (751.5515607999998)
4-[3-[(9E,11E,13E,15E,17E)-henicosa-9,11,13,15,17-pentaenoyl]oxy-2-[(6E,9E,12E)-pentadeca-6,9,12-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
4-[2-[(7E,10E,13E,16E,19E)-docosa-7,10,13,16,19-pentaenoyl]oxy-3-[(5E,8E,11E)-tetradeca-5,8,11-trienoyl]oxypropoxy]-2-(trimethylazaniumyl)butanoate
2-[[(4E,8E,12E)-2-[[(4Z,7Z)-hexadeca-4,7-dienoyl]amino]-3-hydroxydocosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[[(4E,8E,12E)-2-[[(14Z,16Z)-docosa-14,16-dienoyl]amino]-3-hydroxyhexadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(11Z,14Z)-icosa-11,14-dienoyl]amino]octadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(10Z,12Z)-octadeca-10,12-dienoyl]amino]icosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(18Z,21Z)-tetracosa-18,21-dienoyl]amino]tetradeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[[(4E,8E)-2-[[(7Z,10Z,13Z)-hexadeca-7,10,13-trienoyl]amino]-3-hydroxydocosa-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(5Z,8Z,11Z,14Z,17Z)-icosa-5,8,11,14,17-pentaenoyl]amino]octadecoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[[(E)-2-[[(10Z,13Z,16Z,19Z)-docosa-10,13,16,19-tetraenoyl]amino]-3-hydroxyhexadec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[[(4E,8E)-2-[[(10Z,13Z,16Z)-docosa-10,13,16-trienoyl]amino]-3-hydroxyhexadeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-[[(12Z,15Z,18Z,21Z)-tetracosa-12,15,18,21-tetraenoyl]amino]tetradec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[[2-[[(7Z,10Z,13Z,16Z,19Z)-docosa-7,10,13,16,19-pentaenoyl]amino]-3-hydroxyhexadecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[[(4E,8E,12E)-2-[[(9Z,12Z)-heptadeca-9,12-dienoyl]amino]-3-hydroxyhenicosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[[2-[[(11Z,14Z,17Z,20Z,23Z)-hexacosa-11,14,17,20,23-pentaenoyl]amino]-3-hydroxydodecoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(9Z,12Z)-nonadeca-9,12-dienoyl]amino]nonadeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[[(4E,8E,12E)-2-[[(13Z,16Z)-docosa-13,16-dienoyl]amino]-3-hydroxyhexadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[[(4E,8E)-2-[[(12Z,15Z,18Z)-hexacosa-12,15,18-trienoyl]amino]-3-hydroxydodeca-4,8-dienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(9Z,12Z)-octadeca-9,12-dienoyl]amino]icosa-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[[(E)-2-[[(4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoyl]amino]-3-hydroxydocos-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(9Z,12Z,15Z,18Z,21Z)-tetracosa-9,12,15,18,21-pentaenoyl]amino]tetradecoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(13Z,16Z,19Z,22Z,25Z)-octacosa-13,16,19,22,25-pentaenoyl]amino]decoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(3Z,6Z,9Z,12Z,15Z)-octadeca-3,6,9,12,15-pentaenoyl]amino]icosoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-[[(8Z,11Z,14Z,17Z)-icosa-8,11,14,17-tetraenoyl]amino]octadec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-[[(16Z,19Z,22Z,25Z)-octacosa-16,19,22,25-tetraenoyl]amino]dec-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-[[(6Z,9Z,12Z,15Z)-octadeca-6,9,12,15-tetraenoyl]amino]icos-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[[(E)-2-[[(14Z,17Z,20Z,23Z)-hexacosa-14,17,20,23-tetraenoyl]amino]-3-hydroxydodec-4-enoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[hydroxy-[(4E,8E,12E)-3-hydroxy-2-[[(13Z,16Z)-tetracosa-13,16-dienoyl]amino]tetradeca-4,8,12-trienoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[hydroxy-[3-hydroxy-2-[[(15Z,18Z,21Z,24Z,27Z)-triaconta-15,18,21,24,27-pentaenoyl]amino]octoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(11Z,14Z,17Z)-icosa-11,14,17-trienoyl]amino]octadeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[[(4E,8E,12E)-2-[[(11Z,14Z)-henicosa-11,14-dienoyl]amino]-3-hydroxyheptadeca-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[[(4E,8E,12E)-2-[[(9Z,12Z)-hexadeca-9,12-dienoyl]amino]-3-hydroxydocosa-4,8,12-trienoxy]-hydroxyphosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(9Z,12Z,15Z)-octadeca-9,12,15-trienoyl]amino]icosa-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[hydroxy-[(4E,8E)-3-hydroxy-2-[[(10Z,13Z,16Z)-tetracosa-10,13,16-trienoyl]amino]tetradeca-4,8-dienoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
2-[hydroxy-[(E)-3-hydroxy-2-[[(18Z,21Z,24Z,27Z)-triaconta-18,21,24,27-tetraenoyl]amino]oct-4-enoxy]phosphoryl]oxyethyl-trimethylazanium
C43H80N2O6P+ (751.5753690000001)
1-(1Z-octadecenyl)-2-arachidonoyl-sn-glycero-3-phosphoethanolamine
C43H78NO7P (751.5515607999998)
A 1-(alk-1-enyl)-2-acyl-sn-glycero-3-phosphoethanolamine in which the alk-1-enyl and acyl groups are specified as (1Z)-octadecenyl and arachidonoyl respectively.
1-(1Z-octadecenyl)-2-arachidonoyl-sn-glycero-3-phosphoethanolamine zwitterion
C43H78NO7P (751.5515607999998)
A 1-(Z)-alk-1-enyl-2-acyl-sn-glycero-3-phosphoethanolamine zwitterion in which the alk-1-enyl and acyl groups are specified as (1Z-octadecenyl) and arachidonoyl respectively.
MePC(34:5)
C43H78NO7P (751.5515607999998)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Hex1Cer(37:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
Hex1Cer(38:3)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
dMePE(36:5)
C43H78NO7P (751.5515607999998)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved